Pharming Group to acquire Abliva for $66m.

Pharming Group, a global biopharmaceutical company, agreed to acquire Abliva, a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease, for $66m. "The acquisition of Abliva would further strengthen our clinical pipeline with the addition of a therapy, with US launch expected in 2028, aligning with our vision to become a leading global rare disease company. We are pleased that Abliva’s independent Board of Directors and major shareholders recognize the expertise and value Pharming brings to the development and eventual commercialization of KL1333, and unanimously support this transaction. We look forward to welcoming the Abliva team with their strong expertise in mitochondrial research and drug development and to combining with our resources, capabilities and commercial infrastructure to bring this groundbreaking and important medicine to patients and their healthcare providers," Sijmen de Vries, Pharming CEO.